The Maine Wire
  • News
  • Commentary
  • Maine Wire TV
  • Podcasts
  • About
  • Contact
Facebook Twitter Instagram
Trending News
  • Two Men Arrested in Sanford Stabbing and Bike Theft Case
  • South Portland High School Locked Down This Morning After Suspicious Individual Spotted Near Entrance
  • Sen. Dianne Feinstein, Longest-Serving Female Senator, Dead At 90
  • Angus King and West Virginia Senator Partner to Designate September as ‘National Recovery Month’ Amid Rise in Overdoses
  • Senate Unanimously Approves Official Business-Appropriate Dress Code
  • ‘Enough is Enough’: Portland Business Owners Speak Out About Crime and Violence in City’s Homeless Encampments [VIDEO]
  • Low Approval Ratings for Congress and Biden Persist as Government Shutdown Looms: Gallup Poll
  • Sanford Man Stabbed Multiple Times After Having His Bike Stolen Near City’s Homeless Hot Spot
Facebook Twitter Instagram
The Maine Wire
Login
Saturday, September 30
  • News
  • Commentary
  • Maine Wire TV
  • Podcasts
  • About
  • Contact
The Maine Wire
Home » News » Maine gets $2.7 million in pharmaceutical company settlement
News

Maine gets $2.7 million in pharmaceutical company settlement

Steve RobinsonBy Steve RobinsonAugust 30, 2012No Comments3 Mins Read
Facebook Twitter Email LinkedIn Reddit
Share
Facebook Twitter LinkedIn Email

Largest Multistate Consumer Protection Drug Settlement

Attorney General William J. Schneider announced today that Maine, along with 36 other State Attorneys General, reached a record $181 million dollar settlement with Janssen Pharmaceuticals, Inc., a subsidiary of Johnson and Johnson.

A complaint and consent decree filed in Kennebec County Superior Court today resolved claims that Janssen violated the Maine Unfair Trade Practices Act when it improperly marketed the antipsychotic drugs Risperdal, Risperdal Consta, Risperdal M-Tab and Invega for unapproved or off-label uses. Risperdal is among a class of drugs known as atypical or second generation antipsychotics.

Maine will receive $2.7 million as part of the settlement.

The complaint alleges that Janssen promoted Risperdal for off-label uses to both geriatric and pediatric patients, targeting those with Alzheimer’s disease, dementia, depression and anxiety. Risperdal is approved to treat schizophrenia, bipolar disorder and behavior problems in teenagers and children with autism. While doctors may prescribe medicines as they see fit, companies are allowed to promote them for only uses approved by the U.S. Food and Drug Administration (FDA).

“The sales practices of pharmaceutical companies have increasingly come under scrutiny,” said Attorney General Schneider. “As this lengthy investigation and resulting settlement shows, we are determined to curb illegal marketing that puts patients at risk.”

According to the consent judgment, Janssen agreed to change not only how it promotes and markets its atypical antipsychotics but also agreed to refrain from any false, misleading or deceptive promotion of the drugs.  Additionally, for a five-year period, Janssen:

·                           Must clearly and conspicuously disclose, in promotional materials for atypical antipsychotic products, the specific risks identified in the black-box warning on its product labels;

·                           Must present information about effectiveness and risk in a balanced manner in its promotional materials;

·                           Shall not promote its atypical antipsychotics using selected symptoms of the FDA-approved diagnoses unless certain disclosures are made regarding the approved diagnoses;

·                           Shall require its scientifically trained personnel, rather that its sales and marketing personnel, to develop the medical content of scientific communications to address requests for information from health care providers regarding Janssen’s atypical antipsychotics;

·                           Must refrain from  providing samples of its atypical antipsychotics to health care providers whose clinical practices are inconsistent with the FDA-approved labeling of those atypical antipsychotics;

·                           Must not use grants to promote its atypical antipsychotics nor condition medical education funding on Janssen’s approval of speakers or program content;

·                           Must contractually require medical education providers to disclose Janssen’s financial support of their programs and any financial relationship with faculty and speakers; and

·                           Must have policies in place to ensure that financial incentives are not given to marketing and sales personnel that encourage or reward off-label marketing.

This case was handled by Assistant Attorney General Christina Moylan of Attorney General Schneider’s Consumer Protection Division.

The Attorneys General from Florida led the investigation into Janssen’s marketing and promotional practices.  The Attorneys General of the following states and the District of Columbia participated in the settlement: Alabama, Arizona, Colorado, Connecticut, Delaware, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Maryland, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, Wisconsin and Wyoming.

Print Friendly, PDF & Email
Previous ArticleMaine’s new natural-resource department starts today
Next Article Conserved land raises local property values—and property taxes
Steve Robinson
  • Twitter

Steve Robinson is the Editor-in-Chief of The Maine Wire. ‪He can be reached by email at Robinson@TheMaineWire.com.

Related Posts

Two Men Arrested in Sanford Stabbing and Bike Theft Case

September 29, 2023

South Portland High School Locked Down This Morning After Suspicious Individual Spotted Near Entrance

September 29, 2023

Sen. Dianne Feinstein, Longest-Serving Female Senator, Dead At 90

September 29, 2023

Leave A Reply

Recent News

Two Men Arrested in Sanford Stabbing and Bike Theft Case

September 29, 2023

South Portland High School Locked Down This Morning After Suspicious Individual Spotted Near Entrance

September 29, 2023

Sen. Dianne Feinstein, Longest-Serving Female Senator, Dead At 90

September 29, 2023

Angus King and West Virginia Senator Partner to Designate September as ‘National Recovery Month’ Amid Rise in Overdoses

September 29, 2023

Senate Unanimously Approves Official Business-Appropriate Dress Code

September 29, 2023
Newsletter

News

  • News
  • Campaigns & Elections
  • Opinion & Commentary
  • Media Watch
  • Education
  • Media

Maine Wire

  • About the Maine Wire
  • Advertising
  • Contact Us
  • Submit Commentary
  • Complaints
  • Maine Policy Institute

Resources

  • Maine Legislature
  • Legislation Finder
  • Get the Newsletter
  • Maine Wire TV

Facebook Twitter Instagram Steam RSS
  • Post Office Box 7829, Portland, Maine 04112

Type above and press Enter to search. Press Esc to cancel.

Sign In or Register

Welcome Back!

Login below or Register Now.

Lost password?

Register Now!

Already registered? Login.

A password will be e-mailed to you.